



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A61K 31/44, 31/55, 31/135 A61K 31/495, 31/70 // (A61K 31/70 A61K 31/55, 31/44, 31/135 A61K 31/495)</p>	<p>A3</p>	<p>(11) International Publication Number: WO 92/07564</p> <p>(43) International Publication Date: 14 May 1992 (14.05.92)</p>					
<p>(21) International Application Number: PCT/GB91/01890</p> <p>(22) International Filing Date: 29 October 1991 (29.10.91)</p> <p>(30) Priority data:</p> <table border="0"> <tr> <td>9023600-1</td> <td>30 October 1990 (30.10.90)</td> <td>GB</td> </tr> <tr> <td>9023607-6</td> <td>30 October 1990 (30.10.90)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for all designated States except US): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only) : BARRY, David, Walter [US/US]; 1810 South Lakeshore Drive, Chapel Hill, NC 27514 (US). REINHARD, John, Frederick, Jr. [US/US]; 5414 Loyal Place, Durham, NC 27713 (US).</p>	9023600-1	30 October 1990 (30.10.90)	GB	9023607-6	30 October 1990 (30.10.90)	GB	<p>(74) Agent: ROLLINS, A., J.; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 25 June 1992 (25.06.92)</p>
9023600-1	30 October 1990 (30.10.90)	GB					
9023607-6	30 October 1990 (30.10.90)	GB					
<p>(54) Title: METHOD OF TREATING DEMYELINATING DISEASE</p> <p>(57) Abstract</p> <p>A calcium antagonist especially nimodipine, is used for the treatment of demyelinating diseases such as multiple sclerosis. It may be used in combination with an antiviral compound which is active against retroviruses, such as azidothymidine.</p>							

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	Cell Motility and the Cytoskeleton, vol. 10, nos. 1-2, 1988, Alan R. Liss, Inc., A.C. BREUER et al.: "Fast axonal transport alterations in amyotrophic lateral sclerosis (ALS) and in parathyroid hormone (PTH)-treated axons", pages 321-330, see the whole article ---	1-2,4-6 ,9
Y	Toxicol. Appl. Pharmacol., vol. 97, no. 3, 1989, Academic Press, Inc., H.A.N. EL-FAWAL et al.: "Effect of verapamil on organophosphorus-induced delayed neuropathy in hens", pages 500-511, see the whole document ---	1-9
Y	Neurochem. Res., vol. 8, no. 10, 1983, Plenum Publishing Corp., K. YANAGISAWA et al.: "Degradation of myelin basic protein by calcium-activated neutral protease (CANP) in human brain and inhibition by E-64 analogue", pages 1285-1293, see the whole document ---	1-9
A	Journal of Neurology, vol. 233, no. 1, 1986, Springer-Verlag, S. KOMOLY et al.: "Multiple sclerosis: failure of treatment with verapamil in a pilot trial", pages 59-60, see the whole document -----	1,2,4,6 ,8

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim numbers
Authority, namely: because they relate to subject matter not required to be searched by this

2. Claim numbers * because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically
* Claims searched incompletely. 1-4,7-9
In view of the large number of compounds which are possibly included in the term "calcium antagonists" (claim 1), the search was limited to the specific compounds mentioned in claims 5 and 6.

3. Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. claims 1-9
2. claims 10-23

1. As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims:
3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
1-9
4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees